Dave Hathaway is a drug discovery professional with over 15 years of experience supporting small-molecule research and translational science. As Director of Business Development at Enamine, he works at the intersection of medicinal chemistry, AI-driven molecular design, and integrated design–make–test–analyze (DMTA) workflows to help advance novel therapeutics. David’s work is focused not only on building strategic partnerships, but on actively contributing to drug discovery by aligning chemistry, biology, and computational capabilities across organizations. He is particularly interested in collaborative and open-science frameworks that accelerate innovation and contributes to the industries advancement of drug discovery.